The US Food and Drug Administration has granted an accelerated approval to Calquence (acalabrutinib), a new kinase inhibitor for the treatment of adults with mantle cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
